All News

Here’s how I plan to handle sadness, anger, loneliness, regret and guilt that comes with rebuilding my life after cancer.

Although maintenance treatments have helped patients with ovarian cancer live longer, experts note there are still some unmet needs that must be addressed.

Compared with gemcitabine, a modified FOLFIRINOX regimen improved survival rates over five years of follow-up for patients with pancreatic ductal adenocarcinoma who underwent resection, although all patients may not be suitable for this treatment, an expert said.

In honor of Childhood Cancer Awareness Month in September, CURE® compiled a roundup of some of the top stories involving the latest updates in the pediatric cancer space that patients and their families may have missed.

Lumakras outperformed chemotherapy in reducing the risk of progression or death and improving quality of life for patients with KRAS G12C-mutated non-small cell lung cancer, study results showed.

My new cancer treatment hardly has any side effects, making me wonder if researchers are focusing on making their drugs more tolerable for patients.

None of the more than 100 evaluable patients with mismatch repair deficient colon cancer have experienced disease recurrence after treatment with presurgical Opdivo plus Yervoy, according to study results.

Treatment with Libtayo may improve survival over a 30-month period with no new side effects in patients with recurrent or metastatic cervical cancer, opening the doors for an immunotherapy option for these patients.

I was working hard and feeling burnt out, until a cancer diagnosis forced me to slow down and reevaluate the important things in life.

As “Pinktober” approaches, I’m spreading the message that breasts are not needed to live a full life after breast cancer surgery.

This article is sponsored Astellas Pharma US, Inc.

An expert discusses what patients need to know about the recent FDA approval of Enhertu for HER2-mutant non-small cell lung cancer, an aggressive subtype of the disease.

The use of a tumor-infiltrating lymphocyte therapy led to better outcomes than treatment with Yervoy in patients with unresectable, treatment-refractory stage 3/4 melanoma, a type of skin cancer, study results showed.

As National Previvor Day approaches, I’m getting back on my soapbox to discuss genetic testing and family histories of cancer. After all, these discussions could save lives.

With nearly one-year of additional follow-up, adding Keytruda to the combination of abiraterone acetate and the steroid prednisone shows continued benefit in men with metastatic castration-resistant prostate cancer.

When going through treatment for advanced-stage lung cancer, people would often talk to me like I was a child, or ignore me altogether and speak to my husband.

The addition of Cabometyx to the current standard-of-care frontline regimen of Opdivo plus Yervoy improved progression-free survival outcomes in patients with advanced kidney cancer.

Lenvima plus Keytruda improved survival outcomes for patients with pretreated advanced endometrial cancer, according to recent clinical trial data.

BNT211-01, a novel CAR-T cell therapy, was efficacious in treating patients with CLDN6-positive, relapsed/refractory solid cancers, according to a small clinical trial.

Compared to physician’s choice of treatment, Trodelvy improved survival and quality of life in pretreated patients with HR positive/HER2 negative metastatic breast cancer.

Adding the novel drug oleclumab to Imfinzi and chemotherapy for the frontline treatment of advanced triple-negative breast cancer did not improve clinical outcomes, according to recent study findings.

Rubraca improved progression-free survival in patients with BRCA1/2-mutant, platinum-sensitive, relapsed ovarian cancer, according to findings from the ARIEL4 clinical trial.

When my daughter first started cancer treatment, she was brave, but after she understood how difficult it was, she was courageous in continuing.

From actress Jane Fonda giving an update on her cancer, to a patient with leukemia proving he was at the Sept. 11 attacks in New York City with an old newspaper clipping, here’s what’s happening in the cancer space this week.

The Food and Drug Administration issued a statement about the incidence of new cases of rare cancers that have occurred in the scar tissue around breast implants.

The first patient was treated in a phase 2 trial assessing the safety and efficacy of navicixizumab, with or without chemotherapy, in colorectal, gastric, ovarian and breast cancer.

The time after cancer treatment can be overwhelming, but great progress in survivorship care plans over the past two decades has provided better guidance for an easier transition.

When celebrities are diagnosed with cancer, they wield great power to bring awareness to the disease but being in the public eye must be extremely challenging, especially when facing a personal health crisis.